Associated Papers
Aspartylglucosaminuria: Clinical Presentation and Potential Therapies.
Goodspeed K et al.
Journal of Child Neurology, 2021
Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
Banning A et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2018
Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
Saarela J et al.
Human Molecular Genetics, 2001
Aspartylglycosaminuria: biochemistry and molecular biology.
Aronson NN
Biochimica Et Biophysica Acta, 1999
Aspartylglycosaminuria: protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation.
Mononen I et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 1993
Select a paper to view details